Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non–small-cell Lung Cancer-Reference-Cited by-同舟云学术

Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non–small-cell Lung Cancer

Published:2020-11 Issue:6 Volume:21 Page:e647-e653
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Gijtenbeek Rolof G.P.^ORCID,Damhuis Ronald A.M.,Groen Harry J.M.,van der Wekken Anthonie J.,van Geffen Wouter H.

Funder

Novartis

Merck

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference33 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis;Holleman;Onco Targets Ther,2019

3. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer;Soria;N Engl J Med,2018

4. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: a meta-analysis;Yang;Int J Cancer,2017

5. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial;Paz-Ares;Ann Oncol,2017

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review;Advances in Therapy;2024-03-21

2. Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC;Scientific Reports;2023-11-21

3. Lung Cancer in Indonesia;Journal of Thoracic Oncology;2023-09

4. Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status;Cochrane Database of Systematic Reviews;2023-07-07

5. Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study;The Lancet Regional Health - Europe;2023-04